Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study

食管切除术 医学 佐剂 肿瘤科 免疫疗法 食管鳞状细胞癌 新辅助治疗 内科学 基底细胞 食管癌 普通外科 癌症 乳腺癌
作者
Jifeng Feng,Liang Wang,Xun Yang,Qixun Chen
出处
期刊:Frontiers in Immunology [Frontiers Media SA]
卷期号:15: 1456193-1456193 被引量:6
标识
DOI:10.3389/fimmu.2024.1456193
摘要

Background The role of immunotherapy in the adjuvant setting seems promising in recent years. As per the findings of the CheckMate 577 trial, patients with esophageal cancer (EC) who had neoadjuvant chemoradiation with residual pathologic disease should be considered adjuvant immunotherapy (AIT). However, it is unknown if individuals with esophageal squamous cell carcinoma (ESCC) who have received neoadjuvant immunochemotherapy (NICT) followed by radical surgery also require AIT. Methods A retrospective analysis was performed on the data from patients who underwent NICT and radical surgery for ESCC between 2019 and 2020. To compare disease-free survival (DFS) and overall survival (OS), Kaplan-Meier survival curves were produced. To determine the parameters linked to DFS and OS, a Cox model using hazard ratios (HRs) was completed. Results Among the 292 eligible patients, 215 cases with a mean age of 63.3 ± 6.8 years, including 190 (88.4%) men and 25 (11.6%) women, were finally recruited. The percentage of R0 resection was 98.3%. After NICT, 65 (30.2%) patients achieved pathological complete response. AIT was given to 78 (36.3%) patients following radical resection. For all patients, the 3-year DFS and OS were 62.3% and 74.0%, respectively. In terms of 3-year DFS (61.5% vs. 62.8%, P=0.984) or OS (76.9% vs. 72.3%, P=0.384), no statistically significant difference was found between patients with and without AIT. AIT significantly improved survival in patients with ypT+N+ (DFS: 23.9% vs. 38.5%, P=0.036; OS: 37.0% vs. 61.5%, P=0.010), but not in those with ypT0N0 or ypT+N0. It was found that AIT was related to both DFS (HR: 0.297; P<0.001) and OS (HR: 0.321; P=0.001) in patients with ypT+N+. Conclusion In ypT+N+ ESCC patients, AIT after NICT followed by radical surgery reduces the recurrence and death, thereby improving the DFS and OS. Randomized controlled trials ought to be conducted to further assess the results of this retrospective investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
爱静静应助田宇22333采纳,获得30
3秒前
FILPPED完成签到 ,获得积分10
4秒前
牛大锤发布了新的文献求助10
4秒前
xxz发布了新的文献求助10
4秒前
醉熏的身影完成签到 ,获得积分10
6秒前
joan完成签到 ,获得积分10
7秒前
zcg发布了新的文献求助10
9秒前
陈郭安生完成签到,获得积分10
9秒前
illusion完成签到,获得积分10
11秒前
田様应助xxz采纳,获得10
11秒前
李健应助停云采纳,获得10
12秒前
ccshi完成签到,获得积分10
14秒前
Banbor2021完成签到,获得积分0
16秒前
tangz完成签到,获得积分20
16秒前
17秒前
Unique完成签到 ,获得积分10
19秒前
G1997完成签到 ,获得积分10
20秒前
徐老师完成签到 ,获得积分10
21秒前
tangz发布了新的文献求助10
23秒前
停云完成签到,获得积分10
23秒前
小柴柴完成签到 ,获得积分10
24秒前
24秒前
LI完成签到,获得积分10
24秒前
欣慰煎蛋完成签到,获得积分10
24秒前
铁甲小宝完成签到 ,获得积分10
25秒前
26秒前
科研菜菜鸡完成签到,获得积分10
27秒前
浮游应助合适熊猫采纳,获得10
28秒前
浮游应助进口小宵采纳,获得10
29秒前
dyce完成签到,获得积分10
29秒前
停云发布了新的文献求助10
29秒前
圈圈黄完成签到,获得积分10
29秒前
33秒前
皮卡皮卡发布了新的文献求助10
33秒前
hu完成签到,获得积分10
33秒前
dyce发布了新的文献求助20
33秒前
老迟的新瑶完成签到 ,获得积分10
33秒前
在水一方应助余南采纳,获得10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Vertébrés continentaux du Crétacé supérieur de Provence (Sud-Est de la France) 600
A complete Carnosaur Skeleton From Zigong, Sichuan- Yangchuanosaurus Hepingensis 四川自贡一完整肉食龙化石-和平永川龙 600
FUNDAMENTAL STUDY OF ADAPTIVE CONTROL SYSTEMS 500
微纳米加工技术及其应用 500
Nanoelectronics and Information Technology: Advanced Electronic Materials and Novel Devices 500
Performance optimization of advanced vapor compression systems working with low-GWP refrigerants using numerical and experimental methods 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5305727
求助须知:如何正确求助?哪些是违规求助? 4451719
关于积分的说明 13853003
捐赠科研通 4339253
什么是DOI,文献DOI怎么找? 2382411
邀请新用户注册赠送积分活动 1377431
关于科研通互助平台的介绍 1345043